<i>GBP5</i> Serves as a Potential Marker to Predict a Favorable Response in Triple-Negative Breast Cancer Patients Receiving a Taxane-Based Chemotherapy.

Cheng, Shun-Wen; Chen, Po-Chih; Ger, Tzong-Rong; Chiu, Hui-Wen; Lin, Yuan-Feng

GBP5 Serves as a Potential Marker to Predict a Favorable Response in Triple-Negative Breast Cancer Patients Receiving a Taxane-Based Chemotherapy.

Cheng, Shun-Wen; Chen, Po-Chih; Ger, Tzong-Rong; Chiu, Hui-Wen; Lin, Yuan-Feng.

Afiliación

Cheng SW; Department of Biomedical Engineering, Chung Yuan Christian University, Taoyuan City 32023, Taiwan.
Chen PC; Neurology Department, Shuang-Ho Hospital, Taipei Medical University, New Taipei City 235, Taiwan.
Ger TR; Taipei Neuroscience Institute, Taipei Medical University, New Taipei City 23561, Taiwan.
Chiu HW; Department of Neurology, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan.
Lin YF; Department of Biomedical Engineering, Chung Yuan Christian University, Taoyuan City 32023, Taiwan.

J Pers Med ; 11(3)2021 Mar 12.

Article en En | MEDLINE | ID: mdl-33809079

Palabras clave

Akt/mTOR; GBP5; autophagy; chemotherapy; taxane; triple-negative breast cancer

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: J Pers Med Año: 2021 Tipo del documento: Article País de afiliación: Taiwán

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google